Denmark's Zealand Pharma Q1 revenue rises on obesity drug progress

Zealand Pharma A/S

07/05/2026 06:11

Overview

Denmark biotech firm's Q1 revenue rose to DKK 34 mln from DKK 8 mln last year

Company launched USD 200 mln share buyback after positive obesity drug developments

Q1 net operating expenses increased to DKK 573 mln from DKK 393 mln

Outlook

Company maintains 2026 net operating expenses guidance at DKK 2.7-3.3 bln

Result Drivers

OBESITY PIPELINE PROGRESS - Co said positive Phase 2 results for petrelintide and Phase 3 results for survodutide supported revenue growth and strengthened financial outlook

SHARE BUYBACK - Co launched USD 200 mln share buy-back program, attributing financial flexibility to positive developments in obesity programs

Company press release: ID:nGNXbQcqjs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
DKK 34 mln
Q1 Operating Expenses
-DKK 573 mln
Q1 Operating Result
-DKK 539 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Zealand Pharma A/S is DKK500.00, about 58.6% above its May 6 closing price of DKK315.20

The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 31 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)